Table 4.
Review of previous studies with sustained intraocular pressure rise after ranibizumab or bevacizumab intravitreal injection
| Study | Controls | Overall prevalence of OHT (%) | Inclusion of eyes with preexisting history of OHT or glaucoma | Mean number of injections at the time of IOP rise | Postinjection IOP range |
|---|---|---|---|---|---|
| Good et al.12 | - | 13/215 (6) | Yes | Median - 5 | 23-36 |
| Mathalone et al.10 | - | 22/201 (11) | Yes | 5 | 22-36 |
| Adelman et al.13 | - | 4/116 (3.45) | No | 13.3 | 28-36 |
| Hoang et al.15 | Fellow eyes | 32/449 (7.1) | Yes | 25.8 | |
| Wehrli et al.16 | Fellow eyes | 5/302 (1.6) | Yes | 8 | 25-29 |
| Our study | Fellow eyes | 8/796 (1) | No | 1.8 | 23-34 |
OHT: Ocular hypertension, IOP: Intraocular pressure